Adaptimmune Therapeutics PLC (NAS:ADAP)
$ 0.6984 -0.0248 (-3.43%) Market Cap: 178.71 Mil Enterprise Value: 73.46 Mil PE Ratio: 0 PB Ratio: 2.25 GF Score: 64/100

Q1 2024 Adaptimmune Therapeutics PLC Earnings Call Transcript

May 15, 2024 / 12:00PM GMT
Release Date Price: $1.24 (+7.83%)
Operator

All participants, please stand by. Your conference is ready to begin. Good morning, ladies and gentlemen, and welcome to the Adaptimmune Q1 2024 financial and business update conference call. I would now like to turn the meeting over to Ms. Juli Miller. Please go ahead, Ms. Miller.

Juli Miller;Adrian Rawcliffe
Adaptimmune Therapeutics PLC - VP of Corporate Affairs & IR;Adaptimmune Therapeutics PLC -

Good morning, and welcome to our conference call to discuss our first quarter 2024 financial results and business updates. I would ask you to review the full text of our forward-looking statements from this morning's press release. We anticipate making projections during this call and actual results could differ materially due to several factors, including those outlined in our latest filings with the SEC. Adrian Rawcliffe, our Chief Executive Officer, is here with me for the prepared portion of the call and other members of our management team will be available for Q&A.

With that, I'll turn call over to Adrian. Ad?

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot